Equities analysts forecast that Mersana Therapeutics Inc (NASDAQ:MRSN) will announce sales of $430,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Mersana Therapeutics’ earnings. The highest sales estimate is $600,000.00 and the lowest is $250,000.00. Mersana Therapeutics reported sales of $200,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 115%. The company is scheduled to report its next quarterly earnings results on Thursday, August 13th.
On average, analysts expect that Mersana Therapeutics will report full-year sales of $670,000.00 for the current financial year, with estimates ranging from $10,000.00 to $1.90 million. For the next fiscal year, analysts anticipate that the business will post sales of $1.90 million, with estimates ranging from $990,000.00 to $2.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Mersana Therapeutics.
Mersana Therapeutics (NASDAQ:MRSN) last posted its earnings results on Friday, May 8th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.03. Mersana Therapeutics had a negative net margin of 6,099.64% and a negative return on equity of 78.18%. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.37 million.
A number of brokerages recently issued reports on MRSN. ValuEngine upgraded Mersana Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. BidaskClub upgraded Mersana Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, June 17th. BTIG Research increased their target price on Mersana Therapeutics from $21.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, June 24th. Zacks Investment Research upgraded Mersana Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price objective on the stock in a research note on Saturday, March 14th. Finally, Robert W. Baird raised their price objective on Mersana Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research note on Thursday, May 28th. Eight equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $21.10.
In other Mersana Therapeutics news, Director Andrew A. F. Hack bought 3,445,667 shares of the stock in a transaction dated Tuesday, April 7th. The shares were bought at an average cost of $9.43 per share, for a total transaction of $32,492,639.81. Following the purchase, the director now directly owns 538,599 shares of the company’s stock, valued at approximately $5,078,988.57. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Scott D. Sandell sold 20,914 shares of Mersana Therapeutics stock in a transaction on Monday, April 13th. The stock was sold at an average price of $8.50, for a total value of $177,769.00. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRSN. Bank of Montreal Can increased its holdings in Mersana Therapeutics by 43.5% in the 4th quarter. Bank of Montreal Can now owns 4,561 shares of the company’s stock worth $26,000 after acquiring an additional 1,382 shares during the last quarter. Meeder Asset Management Inc. increased its holdings in Mersana Therapeutics by 295.1% in the 1st quarter. Meeder Asset Management Inc. now owns 5,507 shares of the company’s stock worth $32,000 after acquiring an additional 4,113 shares during the last quarter. Citigroup Inc. increased its holdings in Mersana Therapeutics by 210.1% in the 4th quarter. Citigroup Inc. now owns 7,197 shares of the company’s stock worth $41,000 after acquiring an additional 4,876 shares during the last quarter. Prudential Financial Inc. purchased a new stake in Mersana Therapeutics in the 4th quarter worth about $58,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in Mersana Therapeutics in the 4th quarter worth about $60,000. Institutional investors own 72.28% of the company’s stock.
NASDAQ:MRSN traded up $1.12 on Friday, reaching $23.40. 1,929,208 shares of the stock traded hands, compared to its average volume of 1,426,101. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -16.71 and a beta of 2.79. The company’s 50 day moving average is $17.06 and its 200-day moving average is $9.52. The company has a current ratio of 4.59, a quick ratio of 4.59 and a debt-to-equity ratio of 0.24. Mersana Therapeutics has a 1-year low of $1.32 and a 1-year high of $24.07.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.
Recommended Story: What is the Shanghai Stock Exchange Composite Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.